PBTZ 169

Drug Profile

PBTZ 169

Alternative Names: PBTZ169; PBTZ169 NCP

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator A. N. Bach Institute of Biochemistry; Ecole Polytechnique Federale de Lausanne.
  • Developer NEARMEDIC
  • Class Antituberculars; Piperazines
  • Mechanism of Action Cell wall inhibitors; DprE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 22 Feb 2018 Nearmedic terminates a phase II trial in Tuberculosis due to slow enrolment (PO) (NCT03334734)
  • 01 Dec 2017 Phase-I clinical trials in Tuberculosis (In volunteers) in Switzerland (PO) (NCT03423030)
  • 07 Nov 2017 Nearmedic suspends enrolment in a phase IIa trial in Tuberculosis (NCT03334734)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top